Bacterial resistance has become a worldwide concern since patients with infections related to microorganisms have a higher risk to develop the worst outcomes, including death; in addition to greater consumption of hospital resources than those patients who become infected with susceptible microorganisms. Estimates have been made that, if this problem continues increasing, in 2050, there will be ten million deaths worldwide, more than those currently caused by cancer. Gram-negative bacilli, such as Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii are associated with higher rates of both community and hospital-acquired infections and unfortunately have been showing an alarming increase in the rates of resistance. In the last decade, the use of antibiotics has resurfaced, which in the past were discarded due to their toxicity associated, as therapeutic tools for many of these infections; meanwhile, new therapeutic options have emerged on the market that could be viable for the treatment of these bacterial infections depending on the resistance mechanisms involved.
For this topic, we welcome Original Research articles, Reviews, Brief Research Reports, and Mini-Reviews that cover, but are not limited to, the following topics:
- Epidemiological situation of antimicrobial resistance locally or worldwide.
- Multidrug resistant bacterial infections focused on pathogenicity mechanisms, gene and signaling pathways.
- Host-pathogen interactions in multidrug resistance Gram negative infections.
- New or improved diagnostics methods to get better outcome in MDR bacterial infections.
- New or old antimicrobial drugs as possible target to combat antimicrobial resistance.
-Repurposing of molecules with antimicrobial activity against Gram negative bacilli carbapenemases-producers
Bacterial resistance has become a worldwide concern since patients with infections related to microorganisms have a higher risk to develop the worst outcomes, including death; in addition to greater consumption of hospital resources than those patients who become infected with susceptible microorganisms. Estimates have been made that, if this problem continues increasing, in 2050, there will be ten million deaths worldwide, more than those currently caused by cancer. Gram-negative bacilli, such as Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii are associated with higher rates of both community and hospital-acquired infections and unfortunately have been showing an alarming increase in the rates of resistance. In the last decade, the use of antibiotics has resurfaced, which in the past were discarded due to their toxicity associated, as therapeutic tools for many of these infections; meanwhile, new therapeutic options have emerged on the market that could be viable for the treatment of these bacterial infections depending on the resistance mechanisms involved.
For this topic, we welcome Original Research articles, Reviews, Brief Research Reports, and Mini-Reviews that cover, but are not limited to, the following topics:
- Epidemiological situation of antimicrobial resistance locally or worldwide.
- Multidrug resistant bacterial infections focused on pathogenicity mechanisms, gene and signaling pathways.
- Host-pathogen interactions in multidrug resistance Gram negative infections.
- New or improved diagnostics methods to get better outcome in MDR bacterial infections.
- New or old antimicrobial drugs as possible target to combat antimicrobial resistance.
-Repurposing of molecules with antimicrobial activity against Gram negative bacilli carbapenemases-producers